PLoS ONE (Jan 2014)

A treatment with a protease inhibitor recombinant from the cattle tick (Rhipicephalus Boophilus microplus) ameliorates emphysema in mice.

  • Juliana D Lourenço,
  • Luana P Neves,
  • Clarice R Olivo,
  • Adriana Duran,
  • Francine M Almeida,
  • Petra M M Arantes,
  • Carla M Prado,
  • Edna Aparecida Leick,
  • Aparecida S Tanaka,
  • Mílton A Martins,
  • Sergio D Sasaki,
  • Fernanda D T Q S Lopes

DOI
https://doi.org/10.1371/journal.pone.0098216
Journal volume & issue
Vol. 9, no. 6
p. e98216

Abstract

Read online

AimsTo determine whether a serine protease inhibitor treatment can prevent or minimize emphysema in mice.MethodsC57BL/6 mice were subjected to porcine pancreatic elastase (PPE) nasal instillation to induce emphysema and were treated with a serine protease inhibitor (rBmTI-A) before (Protocol 1) and after (Protocol 2) emphysema development. In both protocols, we evaluated lung function to evaluate the airway resistance (Raw), tissue damping (Gtis) and tissue elastance (Htis). The inflammatory profile was analyzed in the bronchoalveolar lavage (BALF) and through the use of morphometry; we measured the mean linear intercept (Lm) (to verify alveolar enlargement), the volume proportion of collagen and elastic fibers, and the numbers of macrophages and metalloprotease 12 (MMP-12) positive cells in the parenchyma. We showed that at both time points, even after the emphysema was established, the rBmTI-A treatment was sufficient to reverse the loss of elastic recoil measured by Htis, the alveolar enlargement and the increase in the total number of cells in the BALF, with a primary decrease in the number of macrophages. Although, the treatment did not control the increase in macrophages in the lung parenchyma, it was sufficient to decrease the number of positive cells for MMP-12 and reduce the volume of collagen fibers, which was increased in PPE groups. These findings attest to the importance of MMP-12 in PPE-induced emphysema and suggest that this metalloprotease could be an effective therapeutic target.